中文摘要：

目的分析自体纯化CD34＋细胞移植治疗中/高危淋巴细胞来源恶性肿瘤的临床疗效。方法 10名中/高危组淋巴细胞来源恶性肿瘤患者行自体纯化CD34＋细胞移植治疗,细胞分选采用cliniMACS系统。计算并统计分选纯度和CD34＋细胞回收率,观察移植相关并发症及患者生存情况。结果纯化后CD34＋细胞纯度为（87.79±3.73）%,回收率达到（65.74±10.37）%。10名患者全部顺利造血重建,感染发生率50%（5/10例）,复发率为20%（2/10例）。结论利用CliniMACS系统进行外周血CD34＋细胞分选,CD34＋细胞纯度、回收率均满意,自体移植后造血功能重建顺利,近期疗效满意。

英文摘要：

Objective To study the effectiveness of CD34＋ selected autologous peripheral blood stem cell transplantation（APBSCT） in medium/high risk lymphocytic malignancies.Methods 10 patients received autologous CD34＋ selected APBSCT,purified by CliniMACS device.The sorting purity and recovery of CD34＋ cells were calculated.Transplant-related complications and prognosis were observed.Results After selection,the mean recovery of CD34＋ cells was（65.74±10.37）% and the mean purity was（87.79±3.73）%.All 10 patients achieved hematopoietic recovery successfully.The rates of infectiou and relapse were 50%（5/10）,and 20%（2/10）,respectively.Conclusion Peripheral blood CD34＋ selection and purification using CliniMACS system are effective with satisfactory purity and recovery.Hemopoietic recovery can be achieved with good short term effectiveness.